[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Eyepoint Inc (EYPT)

Eyepoint Inc (EYPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,027,052
  • Shares Outstanding, K 83,841
  • Annual Sales, $ 31,370 K
  • Annual Income, $ -231,960 K
  • EBIT $ -282 M
  • EBITDA $ -284 M
  • 60-Month Beta 1.76
  • Price/Sales 31.19
  • Price/Cash Flow N/A
  • Price/Book 4.24

Options Overview Details

View History
  • Implied Volatility 337.25% (+20.58%)
  • Historical Volatility 63.66%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 337.25% on 08/06/26
  • IV Low 53.29% on 08/26/25
  • Expected Move (DTE 14) 6.43 (50.15%)
  • Put/Call Vol Ratio 24.45
  • Today's Volume 11,123
  • Volume Avg (30-Day) 2,199
  • Put/Call OI Ratio 2.53
  • Today's Open Interest 75,364
  • Open Int (30-Day) 62,700
  • Expected Range 6.40 to 19.26

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.76
  • Number of Estimates 4
  • High Estimate $-0.48
  • Low Estimate $-0.91
  • Prior Year $-0.85
  • Growth Rate Est. (year over year) +10.59%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.54 +11.18%
on 08/04/26
14.99 -14.41%
on 07/09/26
-1.61 (-11.15%)
since 07/06/26
3-Month
11.30 +13.59%
on 06/09/26
15.92 -19.41%
on 07/01/26
-0.52 (-3.90%)
since 05/06/26
52-Week
9.65 +32.95%
on 11/05/25
19.11 -32.86%
on 12/08/25
+2.25 (+21.27%)
since 08/06/25

Most Recent Stories

More News
EyePoint: Q2 Earnings Snapshot

EyePoint: Q2 Earnings Snapshot

EYPT : 12.83 (+4.73%)
EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments

– Topline data from LUGANO pivotal Phase 3 wet AMD clinical trial expected in August 2026 –– – Topline data from LUCIA pivotal Phase 3 wet AMD clinical trial anticipated in Q4 2026 ––...

EYPT : 12.83 (+4.73%)
EyePoint's Trial Data Window Opens This Quarter: What If the Readout Doesn't Deliver?

Barchart Research What to Expect from EYPT Earnings EYPT Generated August 4, 2026 Current Price $11.70 EPS Estimate $$-0.92 Consensus Rating Strong Buy Average Move 4.69% EyePoint's Trial Data Window Opens...

EYPT : 12.83 (+4.73%)
EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME)

– COMO and CAPRI trials together rapidly enrolled over 480 participants in five months, demonstrating continued enthusiasm for DURAVYU trial participation among retinal specialists and patients –– ...

EYPT : 12.83 (+4.73%)
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious...

EYPT : 12.83 (+4.73%)
EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer

WATERTOWN, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with...

EYPT : 12.83 (+4.73%)
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., June 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious...

EYPT : 12.83 (+4.73%)
EyePoint Pharmaceuticals Eyes Transformative 2026 as DURAVYU Phase 3 Data Nears

Eyepoint Pharmaceuticals (NASDAQ:EYPT) executives said the company remains on track to report top-line data from its Phase 3 wet age-related macular degeneration program for DURAVYU, also known as EYP-1901,...

EYPT : 12.83 (+4.73%)
EyePoint Announces Participation at Upcoming Investor Conferences

WATERTOWN, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious...

EYPT : 12.83 (+4.73%)
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious...

EYPT : 12.83 (+4.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

EYEPOINT INC is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. EYEPOINT INC, formerly known as EyePoint Pharmaceuticals Inc., is based in WATERTOWN, Mass.

See More

Key Turning Points

3rd Resistance Point 14.26
2nd Resistance Point 13.65
1st Resistance Point 13.24
Last Price 12.83
1st Support Level 12.21
2nd Support Level 11.60
3rd Support Level 11.19

See More

52-Week High 19.11
Fibonacci 61.8% 15.50
Fibonacci 50% 14.38
Fibonacci 38.2% 13.26
Last Price 12.83
52-Week Low 9.65

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.